哥伦比亚特区参与者队列中基于MVA的JYNNEOS猴痘疫苗的血清学应答
在美国哥伦比亚特区对猴痘高危人群接种两剂JYNNEOS(IMVANEX)疫苗后评估早期抗体应答。初种者至第42-56天IgG血清阳性率达89.4%,第180天降至67.7%;非初种者分别为92.1%和94.4%。年龄、性别和HIV状态间无显著差异,皮内与皮下混合接种者IgG值显著高于两剂均皮内接种者。
要点
- 初种者第42-56天IgG血清阳性率89.4%,第180天降至67.7%。
- 非初种者第42-56天IgG血清阳性率92.1%,第180天为94.4%。
- 皮内与皮下混合接种者IgG值显著高于两剂均皮内接种者。
核心结论
- 两剂JYNNEOS暴露后预防方案在猴痘高危人群中具有免疫原性,初种者抗体应答在第180天有所下降,非初种者维持较高水平。
研究设计与样本
- 研究纳入在美国哥伦比亚特区接种两剂JYNNEOS(IMVANEX)猴痘疫苗、无特征性皮损或皮疹的猴痘高危人群,且首剂接种当日标本PCR猴痘阴性并提供了基线及至少一个接种后时间点血清样本。
- 检测正痘病毒(OPXV)特异性IgG和IgM ELISA及中和抗体滴度,并分析纵向血清学应答。
- 根据基线IgG和IgM抗体水平将参与者分为初种者和非初种者。
- 采用线性混合效应回归模型分析初种者和非初种者中IgG抗体应答随时间是否随年龄、性别、HIV状态和接种途径变化。
主要发现
- 初种者和非初种者IgG血清阳性率均上升至第42-56天,初种者89.4%、非初种者92.1%可检测到IgG抗体。
- 初种者可检测到IgG抗体的比例至第180天降至67.7%,非初种者仍维持较高水平(94.4%)。
- 中和抗体滴度呈相似模式,接种后初期上升,但初种者至第180天下降。
- 年龄、性别或HIV状态间无显著血清学应答差异。
- 血清学应答随接种途径变化,接受皮内和皮下混合接种者IgG值显著高于两剂均皮内接种者。
关键数值与推荐
- 初种者第42-56天IgG血清阳性率89.4%,第180天67.7%。
- 非初种者第42-56天IgG血清阳性率92.1%,第180天94.4%。
- 接受皮内和皮下混合接种者IgG值显著高于两剂均皮内接种者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed early antibody responses after two doses of JYNNEOS (IMVANEX) mpox vaccine in the District of Columbia (D.C.) in persons at high risk for mpox without characteristic lesions or rash. Participants with PCR mpox negative specimens (oral swab, blood, and/or rectal swab) on the day of receipt of the first vaccine dose and who provided a baseline (day 0) serum sample and at least one serum sample at ∼28, ∼42-56 days, or 180 days post vaccination were included in this analysis. Orthopoxvirus (OPXV)-specific IgG and IgM ELISAs and neutralizing antibody titers were performed, and longitudinal serologic responses were examined. Based on participants' IgG and IgM antibody levels at baseline, they were categorized as naïve or non-naïve. Linear mixed effects regression models were conducted to determine if IgG antibody response over time varied by age, sex, HIV status, and route of administration for both naïve and non-naïve participants. Among both naïve and non-naïve participants IgG seropositivity rates increased until day 42-56, with 89.4 % of naïve and 92.1 % of non-naïve participants having detectable IgG antibodies. The proportion of naive participants with detectable IgG antibodies declined by day 180 (67.7 %) but remained high among non-naïve participants (94.4 %). Neutralizing antibody titers displayed a similar pattern, increasing initially post vaccination but declining by day 180 among naïve participants. There were no significant serologic response differences by age, sex, or HIV status. Serologic response did vary by route of vaccine administration, with those receiving a combination of intradermal and subcutaneous doses displaying significantly higher IgG values than those receiving both doses intradermally. These analyses provide initial insights into the immunogenicity of a two-dose JYNNEOS PEP regimen in individuals at high risk of mpox exposure in the United States.
引用
- Griffin I, Berry I, Navarra T, et al. Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.). Vaccine. 2024. PMID: 38762357. doi:10.1016/j.vaccine.2024.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。